← All trials
NCT03023540
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 7, 2017
- Primary completion
- Jan 1, 2019
- Completion date
- Jan 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 323
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Pharnext SALead sponsor
- Seton Hall UniversityOverall official - principal investigator
- University of ManchesterOverall official - principal investigator
- University of MunsterOverall official - principal investigator
- Aix-University of MarseilleOverall official - principal investigator
- INC ResearchCollaborator
- Synteract, Inc.Collaborator
- University of AmsterdamOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.